Edgewood Oncology
Signal active
Organization
Contact Information
Overview
Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs.
About
Industries
Biotechnology
Founded
2023
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Edgewood Oncology headquartered in United States, North America, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $80.0M in funding across 4 round(s). With a team of 1-10 employees, Edgewood Oncology is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Edgewood Oncology, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
1
Lead Investors
0
Total Funding Amount
$20.0M
Details
1
Edgewood Oncology has raised a total of $20.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2024 | Early Stage Venture | 20.0M |
Investors
Edgewood Oncology is funded by 3 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Dan Janney | - | FUNDING ROUND - Dan Janney | 20.0M |
| Edgewood Oncology | - | FUNDING ROUND - Edgewood Oncology | 20.0M |
| Alta Partners | - | FUNDING ROUND - Alta Partners | 20.0M |
Recent Activity
There is no recent news or activity for this profile.